Patent · US Active

Method for reprogramming blood to induced pluripotent stem cells

US11970714B2 · kind B2 · utility

0Cited by

15References

22Claims

0Family size

Assignee

Cedars Sinai Medical Center · US

Inventors

Dhruv Sareen · Deer Lake Highlands, US
Loren A. Ornelas · Los Angeles, US
Clive Svendsen · Santa Monica, US

Key dates

Filing date	Jul 2, 2020
Grant date	Apr 30, 2024
Priority date	—
Expiry date	Oct 30, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2533/52
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.